Ligand-engaged Urokinase-type Plasminogen Activator Receptor and Activation of the CD11b/CD18 Integrin Inhibit Late Events of HIV Expression in Monocytic Cells

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2008 Oct 23

PMID 18941116

Citations 8

Authors

Massimo Alfano

Samanta A Mariani

Chiara Elia

Ruggero Pardi

Francesco Blasi

Guido Poli

Affiliations

Soon will be listed here.

Abstract

Urokinase-type plasminogen activator (uPA) signaling via its receptor uPAR inhibits late events in HIV-1 replication in acutely infected primary monocyte-derived macrophages (MDMs) and promonocytic U937 cells. Here we show that U937-derived, chronically infected U1 cells stimulated with phorbol 12-myristate 13-acetate (PMA) express integrins, uPA, and soluble uPAR at levels similar to those of MDMs. uPA inhibited HIV expression in U1 cells incubated with either PMA or tumor necrosis factor-alpha (TNF-alpha), but not with other HIV-inductive cytokines or lipopolysaccharide. Of interest, only PMA and TNF-alpha, but not other HIV-inductive stimuli, induced surface expression of the alpha(M) chain CD11b in U1 cells constitutively expressing CD18, the beta(2) chain of the Mac-1 integrin. Like uPA, fibrinogen, a Mac-1 (CD11b/CD18) ligand, and M25, a peptide homologous to a portion of the beta-propeller region of CD11b preventing its association with uPAR, inhibited HIV virion release in PMA-stimulated U1 cells. Both uPAR small-interference RNA (siRNA) and soluble anti-beta(1)/-beta(2) monoclonal antibodies abolished the anti-HIV effects of uPA, whereas CD11b siRNA reversed the anti-HIV effect of M25, but not that induced by uPA. Thus, either uPA/uPAR interaction, Mac-1 activation, or prevention of its association with uPAR triggers a signaling pathway leading to the inefficient release of HIV from monocytic cells.

Citing Articles

Aflatoxin B1 decreased flesh flavor and inhibited muscle development in grass carp ().

He X, Zeng Z, Jiang W, Wu P, Liu Y, Kuang S Anim Nutr. 2024; 18:27-38.

PMID: 39026602 PMC: 11254537. DOI: 10.1016/j.aninu.2024.03.012.

ALG3 Promotes Peritoneal Metastasis of Ovarian Cancer through Increasing Interaction of α1,3-mannosylated uPAR and ADAM8.

Cui X, Pei X, Wang H, Feng P, Qin H, Liu S Cells. 2022; 11(19).

PMID: 36231102 PMC: 9563302. DOI: 10.3390/cells11193141.

Modulation of Cellular Function by the Urokinase Receptor Signalling: A Mechanistic View.

Alfano D, Franco P, Stoppelli M Front Cell Dev Biol. 2022; 10:818616.

PMID: 35493073 PMC: 9045800. DOI: 10.3389/fcell.2022.818616.

Cellular localization, invasion, and turnover are differently influenced by healthy and tumor-derived extracellular matrix.

Genovese L, Zawada L, Tosoni A, Ferri A, Zerbi P, Allevi R Tissue Eng Part A. 2014; 20(13-14):2005-18.

PMID: 24498848 PMC: 4086800. DOI: 10.1089/ten.TEA.2013.0588.

HIV-1 infected lymphoid organs upregulate expression and release of the cleaved form of uPAR that modulates chemotaxis and virus expression.

Nebuloni M, Zawada L, Ferri A, Tosoni A, Zerbi P, Resnati M PLoS One. 2013; 8(7):e70606.

PMID: 23923008 PMC: 3726662. DOI: 10.1371/journal.pone.0070606.

References

Sidenius N, Nebuloni M, Sala S, Zerbi P, Price R, Gisslen M . Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease. J Neuroimmunol. 2004; 157(1-2):133-9. DOI: 10.1016/j.jneuroim.2004.08.038. View

Sporer B, Koedel U, Popp B, Paul R, Pfister H . Evaluation of cerebrospinal fluid uPA, PAI-1, and soluble uPAR levels in HIV-infected patients. J Neuroimmunol. 2005; 163(1-2):190-4. DOI: 10.1016/j.jneuroim.2005.02.013. View

Shushakova N, Tkachuk N, Dangers M, Tkachuk S, Park J, Zwirner J . Urokinase-induced activation of the gp130/Tyk2/Stat3 pathway mediates a pro-inflammatory effect in human mesangial cells via expression of the anaphylatoxin C5a receptor. J Cell Sci. 2005; 118(Pt 12):2743-53. DOI: 10.1242/jcs.02409. View

Maslin C, Kedzierska K, Webster N, Muller W, Crowe S . Transendothelial migration of monocytes: the underlying molecular mechanisms and consequences of HIV-1 infection. Curr HIV Res. 2005; 3(4):303-17. DOI: 10.2174/157016205774370401. View

Rizzi C, Crippa M, Jeeninga R, Berkhout B, Blasi F, Poli G . Pertussis toxin B-oligomer suppresses IL-6 induced HIV-1 and chemokine expression in chronically infected U1 cells via inhibition of activator protein 1. J Immunol. 2006; 176(2):999-1006. DOI: 10.4049/jimmunol.176.2.999. View

Ostrowski S, Katzenstein T, Pedersen M, Hoyer-Hansen G, Gerstoft J, Pedersen B . Plasma levels of intact and cleaved urokinase receptor decrease in HIV-1-infected patients initiating highly active antiretroviral therapy. Scand J Immunol. 2006; 63(6):478-86. DOI: 10.1111/j.1365-3083.2006.001768.x. View

Cassol E, Alfano M, Biswas P, Poli G . Monocyte-derived macrophages and myeloid cell lines as targets of HIV-1 replication and persistence. J Leukoc Biol. 2006; 80(5):1018-30. DOI: 10.1189/jlb.0306150. View

Wilflingseder D, Stoiber H . Float on: lipid rafts in the lifecycle of HIV. Front Biosci. 2006; 12:2124-35. DOI: 10.2741/2216. View

Binder B, Mihaly J, Prager G . uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemost. 2007; 97(3):336-42. View

10.

Stillfried G, Saunders D, Ranson M . Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity. Breast Cancer Res. 2007; 9(1):R14. PMC: 1851380. DOI: 10.1186/bcr1647. View

11.

Deneka M, Pelchen-Matthews A, Byland R, Ruiz-Mateos E, Marsh M . In macrophages, HIV-1 assembles into an intracellular plasma membrane domain containing the tetraspanins CD81, CD9, and CD53. J Cell Biol. 2007; 177(2):329-41. PMC: 2064140. DOI: 10.1083/jcb.200609050. View

12.

Welsch S, Keppler O, Habermann A, Allespach I, Krijnse-Locker J, Krausslich H . HIV-1 buds predominantly at the plasma membrane of primary human macrophages. PLoS Pathog. 2007; 3(3):e36. PMC: 1829407. DOI: 10.1371/journal.ppat.0030036. View

13.

Sidenius N, Sier C, Ullum H, Pedersen B, Lepri A, Blasi F . Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood. 2000; 96(13):4091-5. View

14.

Bouhlal H, Galon J, Kazatchkine M, Fridman W, Sautes-Fridman C, Haeffner Cavaillon N . Soluble CD16 inhibits CR3 (CD11b/CD18)-mediated infection of monocytes/macrophages by opsonized primary R5 HIV-1. J Immunol. 2001; 166(5):3377-83. DOI: 10.4049/jimmunol.166.5.3377. View

15.

Wada M, Wada N, Shirono H, Taniguchi K, Tsuchie H, Koga J . Amino-terminal fragment of urokinase-type plasminogen activator inhibits HIV-1 replication. Biochem Biophys Res Commun. 2001; 284(2):346-51. DOI: 10.1006/bbrc.2001.4965. View

16.

Resnati M, Pallavicini I, Wang J, Oppenheim J, Serhan C, Romano M . The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci U S A. 2002; 99(3):1359-64. PMC: 122195. DOI: 10.1073/pnas.022652999. View

17.

Ross G . Role of the lectin domain of Mac-1/CR3 (CD11b/CD18) in regulating intercellular adhesion. Immunol Res. 2002; 25(3):219-27. DOI: 10.1385/IR:25:3:219. View

18.

Alfano M, Sidenius N, Panzeri B, Blasi F, Poli G . Urokinase-urokinase receptor interaction mediates an inhibitory signal for HIV-1 replication. Proc Natl Acad Sci U S A. 2002; 99(13):8862-7. PMC: 124389. DOI: 10.1073/pnas.142078099. View

19.

Blasi F, Carmeliet P . uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002; 3(12):932-43. DOI: 10.1038/nrm977. View

20.

Stoiber H, Speth C, Dierich M . Role of complement in the control of HIV dynamics and pathogenesis. Vaccine. 2003; 21 Suppl 2:S77-82. DOI: 10.1016/s0264-410x(03)00203-2. View